Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma.

MLA

Wang, Xiao-Wei, et al. “Clinical Significance of Upregulated Rho GTPase Activating Protein 12 Causing Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma.” World Journal of Gastrointestinal Oncology, vol. 16, no. 10, Oct. 2024, pp. 4244–63. EBSCOhost, https://doi.org/10.4251/wjgo.v16.i10.4244.

APA

Wang, X.-W., Tang, Y.-X., Li, F.-X., Wang, J.-L., Yao, G.-P., Zeng, D.-T., Tang, Y.-L., Chi, B.-T., Su, Q.-Y., Huang, L.-Q., Qin, D.-Y., Chen, G., Feng, Z.-B., & He, R.-Q. (2024). Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 16(10), 4244–4263. https://doi.org/10.4251/wjgo.v16.i10.4244

Chicago

Wang, Xiao-Wei, Yu-Xing Tang, Fu-Xi Li, Jia-Le Wang, Gao-Peng Yao, Da-Tong Zeng, Yu-Lu Tang, et al. 2024. “Clinical Significance of Upregulated Rho GTPase Activating Protein 12 Causing Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma.” World Journal of Gastrointestinal Oncology 16 (10): 4244–63. doi:10.4251/wjgo.v16.i10.4244.